Skip to main content
. 2019 Jul 4;11(7):315. doi: 10.3390/pharmaceutics11070315

Figure 2.

Figure 2

In vitro release studies showing (a) cumulative release of TAF from implants of differing surface areas and (b) daily release rates of TAF at day = 24 for implants with different surface areas. All implants were fabricated with Sigma-PCL, 100 µm wall thickness and a formulation of 2:1, TAF:castor oil. Surface areas were normalized according to the theoretical surface area for implant of 10, 40, 70 mm in length. Three implants were tested per condition.